

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1935PLC025878

<p>BSE Limited 1st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p> <p>Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan</p> <p>Code: 532321</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p> <p>Kind Attn.: Famroze Pochara Asst. Vice President</p> <p>Symbol: CADILAHC</p>
Date: May 13, 2016	
Re.: Press Release	

Dear Sir / Madam,

We are forwarding herewith a copy of the Press Release proposed to be published in the newspapers in the matter of audited financial results for the quarter / year ended on March 31, 2016.


We request your good office to receive the same in order.

Thanking you,

Yours faithfully,
FOR CADILA HEALTHCARE LIMITED



UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus Cadila's Net Profit up by 32% to Rs. 1523 crore

Ahmedabad, May 13, 2016

Announcing the results for the year ended 31st March 2016, Zydus Cadila registered a Net Profit of Rs. 1523 crores, up by 32% from Rs. 1151 crores, on a consolidated basis. Consolidated total income from operations of the the company grew by 14% during the year to Rs. 9838 crores from Rs. 8651 crores registered last year.

For the fourth quarter ended 31st March 2016, the group registered total income from operations of Rs. 2449 crores, up by 7% from Rs. 2288 crores registered in the corresponding period last year on a consolidated basis. Net Profit for the same period stood at Rs. 389 crores, which was up by 11%.

The company's formulations business in the US was the largest contributor to the consolidated revenues and the key driver of the overall growth. During the year, the formulations in US business grew by 19% and crossed US\$ 600 Mio. mark in sales for the first time. Strengthening its regulatory pipeline, the company filed 30 ANDAs during the year with the US FDA, taking the cumulative filings to 269. The company received 10 ANDA approvals during the year taking the total to 103 product approvals.

The company's formulations business in India grew by 11% during the year on the back of launch of more than 40 new products, including line extensions. The company's formulations business in emerging markets grew by 17%.
